Submit your Defective Drugs claim details for a free, no obligation case review.
Get Started:
drug_recall avandiaAvandia was FDA approved in May 1999 for the treatment of type 2 diabetes. An oral agent, Avandia is supposed to be used in addition to diet and exercise to improve blood sugar control. In March 2000, the Public Citizen consumer group petitioned the FDA for the immediate revision of "inadequate, misleading, and potentially dangerous professional product labeling" for the diabetes drugs referred to as "glitazones", which include Rezulin, Avandia and Actos.
According to the consumer group, Avandia and the other two glitazone drugs were approved as adjuncts to diet and exercise in order to improve blood sugar control in type 2 diabetes patients but the drug labeling was inadequate and did not mention safety and efficacy information that appeared relevant to all three drugs in the class. The failure to include the lack of efficacy compared to already available drugs, in addition to the deterioration of blood sugar levels when patients are switched from other anti-diabetic drugs to Avandia was not mentioned.
Avandia side effects, such as liver toxicity, heart function effects, weight gain, edema, anemia, low blood pressure, elevated lipid levels, and possible progesterone level changes were also nowhere to be found on Avandia and other glitazone labelings. Rezulin was the first drug of the Avandia inclusive class to be approved and was already banned in Great Britain at the time of the Public Citizen FDA petition. By 2000, Rezulin was recalled in the U.S. because of the instances of liver damage leading to death, necessity of liver transplants, and damage that occurred and has led to thousands of Rezulin lawsuits.
GlaxoSmithKline, Avandia''s manufacturer, is currently investing $300 million for long-term Avandia side effects studies. It can take years and years to better determine safety concerns beyond the FDA approval process because of the clinical trials that fail to show the overall effect a drug can have on a wider scope of patients. While many studies can involve a high number of people, it will still leave out many groups or not be able to show a drug risk that becomes more apparent as adverse event reports are made. In recent years, finding subjects is considered the number one obstacle in getting drug trials completed.
PPH, an uncommon clinical syndrome causing the blood pressure in the pulmonary artery to rise far above normal levels, is a difficult diagnosis of exclusion that has been linked to the use of some drugs. Due to the complexity of the rare lung disorder, it is often mistaken for other things. Avandia side effects include edema, the buildup of fluid that can cause swelling in ankles or legs.
Commonly, PPH sufferers will show symptoms that often include edema. Since the PPH is commonly not diagnosed until it has progressed a long way and the side effects have become apparent, patients should be aware of Avandia side effects that may be indicators of more serious conditions. Type 2 diabetes currently affects about 16 million Americans but the Avandia side effects should be fully understood before choosing the treatment method. Avandia is not appropriate for all patients and some Avandia side effects can be significantly more prevalent in certain people.
A government run diabetes trial was halted 18 months early after a safety analysis revealed an increased risk of death in patients whose blood sugar levels dipped too low.
The 10,000 patient trial was examining the effectiveness of aggressive ...
A new study published in the Journal of the American Medical Association reaffirms previous findings about the diabetes drug Avandia—that is, it carries a significantly increased risk of heart failure, heart attack, and death.
Ob...
At the urging of the Food and Drug Administration, GlaxoSmithKline is adding a new warning to its once-popular diabetes drug Avandia . An increased risk of heart attack will now appear ...